<DOC>
	<DOCNO>NCT02282813</DOCNO>
	<brief_summary>This extension study subject previously enrol study CTAP101-CL-3001 CTAP101-CL-3002 allow long term evaluation safety efficacy CTAP101 Capsules reduce elevate intact parathyroid hormone ( iPTH ) correct vitamin D insufficiency stage 3 4 chronic kidney disease patient .</brief_summary>
	<brief_title>Extension Study CTAP101-CL-3001 CTAP101-CL-3002</brief_title>
	<detailed_description>Only subject previously enrol study CTAP101-CL-3001 CTAP101-CL-3002 eligible participate extension study . This phase 3 , open-label study CTAP101 Capsules , without add-on vitamin D hormone therapy .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>1 alpha-hydroxyergocalciferol</mesh_term>
	<mesh_term>Calcifediol</mesh_term>
	<criteria>Completed either phase 3 doubleblind , placebocontrolled study , CTAP101CL3001 CTAP101CL3002 Taking 1000 mg/day elemental Ca willing/able remain dose duration study Taking 1600 IU/dose vitamin D ( ergocalciferol cholecalciferol ) therapy willing/able remain stable dose vitamin D study Willing able comply study instruction commit clinic visit duration study Female subject childbearing potential must neither pregnant lactating must negative urine pregnancy test All female subject childbearing potential male subject female partner childbearing potential must agree use effective contraception ( eg , implant , injectables , combine oral contraceptive , intrauterine device , sexual abstinence , vasectomy vasectomized partner ) duration study Have ability read understand subject Informed Consent Form ( ICF ) . Subjects legal representative must sign ICF . Use pharmacological dose ergocalciferol cholecalciferol ( monthly equivalent 50,000 IU 1250 µg , eg , Drisdol® ) bisphosphonate therapy Use bone metabolism therapy ( exception stable dos bisphosphonates denosumab [ Xgeva® Prolia® ] ) may interfere study endpoint Concomitant serious illness medical condition , malignancy , human immunodeficiency virus , significant gastrointestinal hepatic disease cardiovascular event hepatitis opinion investigator may worsen and/or interfere participation study Neurological/psychiatric disorder , include psychotic disorder dementia , condition reason , opinion investigator make adherence treatment followup schedule unlikely Known suspect hypersensitivity constituent either investigational product ( CTAP101 ) adjunctive vitamin D hormone therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Parathyroid Diseases</keyword>
	<keyword>Renal Insufficiency</keyword>
	<keyword>Kidney Failure , Chronic</keyword>
	<keyword>Hyperparathyroidism , Secondary</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>Hyperparathyroidism</keyword>
	<keyword>Kidney Diseases</keyword>
	<keyword>Kidney Failure</keyword>
	<keyword>Renal Insufficiency , Chronic</keyword>
</DOC>